Stocks Health care SXTP
NASDAQ · Health care60 Degrees Pharmaceuticals, Inc. (SXTP)
60 Degrees Pharmaceuticals, Inc. brought in $1.1M of revenue over the twelve months to June 30, 2026, up 73.2% from a year earlier. It posted a net loss of $8.1M. In fiscal 2025 capital spending exceeded operating cash flow by $7M. At June 30, 2026 it held $1M in cash against $150K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about 60 Degrees Pharmaceuticals, Inc.
- Net worth
- 60 Degrees Pharmaceuticals, Inc. has a market value (market cap) of $1.8M at the latest share price, and shareholders' equity of $2.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1M (+65.5% year on year), with a net loss of $7.4M. Over the 12 months to June 30, 2026: revenue $1.1M, net loss $8.1M.
- Cash flow
- In fiscal 2025 operations used $6.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- 60 Degrees Pharmaceuticals, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What 60 Degrees Pharmaceuticals, Inc. does
60 Degrees Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SXTP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1M | -$7.4M | -$11.73 | -$7M |
| 2024 | $607.6K | -$7.9M | -$74.17 | -$5.8M |
| 2023 | $253.6K | -$3.8M | -$236.62 | -$4.6M |
| 2023 | $223.2K | -$6.2M | -$623.83 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SXTP ranks in Health care
Latest SEC filings
What 60 Degrees Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026
- September 14, 2026Other event 8-K
- September 8, 2026
- August 17, 2026Form DEL AM filing DEL AM
- August 14, 2026
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 106% to $207.9K versus the same quarter last year; diluted EPS -$0.90 versus -$5.01.
- August 6, 2026
- August 5, 2026Passive stake (5% or more) SCHEDULE 13G
- August 4, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running 60 Degrees Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 12, 2026 | Dow Geoffrey SPresident and CEO, Director | Bought | 7,350 | $10.1K |
| December 15, 2025 | Dow Geoffrey SPresident and CEO, Director | Bought | 9,670 | $7.8K |
| December 11, 2025 | Dow Geoffrey SPresident and CEO, Director | Bought | 3,613 | $3.3K |
| December 10, 2025 | Dow Geoffrey SPresident and CEO, Director | Bought | 9,350 | $8.9K |
Who owns SXTP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Knight Therapeutics Inc.13G, passive | 19.85% | July 29, 2026 |
| Mitchell P. Kopin13G, passive with 2 related filers | 9.1% | May 13, 2026 |
| CVI Investments, Inc.13G, passive with 1 related filers | 7% | May 15, 2026 |
| Lind Global Fund III LP13G, passive with 2 related filers | 5.45% | August 5, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 24,131 shares in total, about $12.6K at the last price.
| Holder | Shares |
|---|---|
| Dow Geoffrey SPresident and CEO, Director | 24,131 |
Questions about SXTP
What does 60 Degrees Pharmaceuticals, Inc. do?
60 Degrees Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as SXTP. Its shares trade on NASDAQ under the ticker SXTP.
What is 60 Degrees Pharmaceuticals, Inc.'s net worth?
60 Degrees Pharmaceuticals, Inc. has a market value (market cap) of $1.8M at the latest share price, and shareholders' equity of $2.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is 60 Degrees Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $8.1M on revenue of $1.1M.
How much revenue does 60 Degrees Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 60 Degrees Pharmaceuticals, Inc. reported revenue of $1.1M. That is 73.2% more than a year earlier.
When did 60 Degrees Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from October 6, 2026.
When is 60 Degrees Pharmaceuticals, Inc.'s next earnings report?
60 Degrees Pharmaceuticals, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SXTP with
Follow SXTP
Get an email when 60 Degrees Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values 60 Degrees Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.